Targeted elimination of prostate cancer by genetically directed human T lymphocytes

Cancer Research

Volumn 65, Issue 19, 2005, Pages 9080-9088

  Gade, Terence P F ^a   Hassen, Waleed ^a   Santos, Elmer ^a   Gunset, Gertrude ^a   Saudemont, Aurore ^a   Gong, Michael C ^a   Brentjens, Renier ^a   Zhong, Xiao Song ^a   Stephan, Matthias ^a   Stefanski, Jolanta ^a   Lyddane, Clay ^a   Osborne, Joseph R ^a   Buchanan, Ian M ^a   Hall, Simon J ^b   Heston, Warren D ^c   Rivière, Isabelle ^a   Larson, Steven M ^a   Koutcher, Jason A ^a   Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; EFFECTOR CELL; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; NEOVASCULARIZATION (PATHOLOGY); PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR MODEL;

ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE PROTEINS; MICE; MICE, SCID; NIH 3T3 CELLS; PROSTATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 25444524262     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0436     Document Type: Article

References (50)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-34.
3. Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 2000;48:507-12.
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
5. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-39.
6. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999;11:263-70.
7. Cho HJ, Bhardwaj N. Against the self: dendritic cells versus cancer. APMIS 2003;111:805-17.
8. Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002;109:409-17.
9. Wolchok JD, Gregor PD, Nordquist LT, Slovin SF, Scher HI. DNA vaccines: an active immunization strategy for prostate cancer. Semin Oncol 2003;30:659-66.
10. McNeel DG, Nguyen LD, Disis ML. Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res 2001;61:5161-7.
11. Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 1998;161:3186-94.
12. Lu J, Cells E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002;62:5807-12.
13. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998;95:1735-40.
14. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 2003;24:335-42.
15. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003;3:35-45.
16. Geiger TL, Jyothi MD. Development and application of receptor-modified T lymphocytes for adoptive immunotherapy. Transfus Med Rev 2001;15:21-34.
17. Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 2001;248:67-76.
18. Ma Q, Gonzalo-Daganzo RM, Junghans RP. Genetically engineered T cells as adoptive immunotherapy of cancer. Cancer Chemother Biol Response Modif 2002;20:315-41.
19. Brocker T. Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 2000;96:1999-2001.
20. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999;1:123-7.
21. Geiger TL, Nguyen P, Leitenberg D, Flavell RA. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood 2001;98:2364-71.
22. Haynes NM, Trapani JA, Teng MW, et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002;169:5780-6.
23. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRCζ/CD28 receptor. Nat Biotechnol 2002;20:70-5.
24. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-11.
25. Gong MC, Chang SS, Watt F, et al. Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. Mol Urol 2000;4:217-22, discussion 223.
26. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003;9:279-86.
27. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A 1995;92:6733-7.
28. + memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003;101:4260-6.
29. O'Keefe DS, Uchida A, Bacich DJ, et al. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 2000;45:149-57.
30. Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 1995;52:403-13.
31. + T cells by B7-transfected melanoma cells. Science 1993;259:368-70.
32. Bai XF, Bender J, Liu J, et al. Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. J Immunol 2001;167:3936-43.
33. Prilliman KR, Lemmens EE, Palioungas G, et al. Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL. J Immunol 2002;169:4094-7.
34. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-64.
35. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate cancer trends 1973-1995, SEER Program. Bethesda (MD): National Cancer Institute; 1999.
36. Pound CR. Evaluation and treatment of men with biochemical prostate specific antigen recurrence following definitive therapy for clinically localized prostate cancer. Rev Urol 2001;3:72-84.
37. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-83.
38. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-7.
39. Haynes NM, Snook MB, Trapani JA, et al. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-ζ vs Fcε RI-γ. J Immunol 2001;166:182-7.
40. Kershaw MH, Westwood JA, Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol 2002;20:1221-7.
41. Wang G, Chopra RK, Royal RE, Yang JC, Rosenberg SA, Hwu P. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-γ chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nat Med 1998;4:168-72.
42. Pinthus JH, Waks T, Kaufman-Francis K, et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res 2003;63:2470-6.
43. Haynes NM, Trapani JA, Teng MW, et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002;100:3155-63.
44. Patel SD, Ge Y, Moskalenko M, McArthur JG. Anti-tumor CC49-ζ CD4 T cells possess both cytolytic and helper functions. J Immunother 2000;23:661-8.
45. Riviere I, Sadelain M, Brentjens RJ. Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes. Curr Hematol Rep 2004;3:290-7.
46. Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate 2004;61:12-25.
47. Pinthus JH, Waks T, Malina V, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest 2004;114:1774-81.
48. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003;170:1717-21.
49. l77Lutetium. American Urological Association annual meeting; Chicago, IL. 2003.
50. O'Keefe DS, Bacich DJ, Heston WD. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate 2004;58:200-10.